Head-To-Head Contrast: Taysha Gene Therapies (TSHA) vs. Its Rivals

Taysha Gene Therapies (NASDAQ:TSHA) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare Taysha Gene Therapies to similar companies based on the strength of its analyst recommendations, institutional ownership, dividends, risk, earnings, valuation and profitability.

Institutional & Insider Ownership

77.7% of Taysha Gene Therapies shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 3.5% of Taysha Gene Therapies shares are held by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Taysha Gene Therapies and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Taysha Gene Therapies	$9.77 million	-$109.00 million	-9.98
Taysha Gene Therapies Competitors	$727.61 million	$12.25 million	-9.90

Taysha Gene Therapies’ competitors have higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Taysha Gene Therapies and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Taysha Gene Therapies	1	0	12	2	3.00
Taysha Gene Therapies Competitors	9792	15073	45358	1574	2.54

Taysha Gene Therapies presently has a consensus target price of $12.77, suggesting a potential upside of 204.68%. As a group, “Biotechnology” companies have a potential upside of 99.28%. Given Taysha Gene Therapies’ stronger consensus rating and higher possible upside, equities analysts plainly believe Taysha Gene Therapies is more favorable than its competitors.

Profitability

This table compares Taysha Gene Therapies and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Taysha Gene Therapies	N/A	-56.19%	-41.84%
Taysha Gene Therapies Competitors	-9,051.23%	-201.20%	-30.64%

Risk and Volatility

Taysha Gene Therapies has a beta of 1.36, meaning that its stock price is 36% more volatile than the S&P 500. Comparatively, Taysha Gene Therapies’ competitors have a beta of 1.15, meaning that their average stock price is 15% more volatile than the S&P 500.

Summary

Taysha Gene Therapies beats its competitors on 9 of the 13 factors compared.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.